<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <title>Declarations</title>
 <notes id="FPar1">
  <title>Ethical approval and consent to participate</title>
  <p id="Par57">The study was reviewed and approved by the London South East NHS Ethics Committee, the UK Medicines and Healthcare products Regulatory Agency and the UK Health Research Authority (IRAS ID 244863). The study is performed in compliance with the declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent is obtained from each patient before study entry.</p>
 </notes>
 <notes id="FPar2">
  <title>Consent for publication</title>
  <p id="Par58">Not applicable.</p>
 </notes>
 <notes id="FPar3" notes-type="COI-statement">
  <title>Competing interests</title>
  <p id="Par59">DJP received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from Bristol Myers Squibb (BMS) and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. AC received speaker fess and grant consultancies by BMS, MSD, Roche, Astra Zeneca, Novartis and Astellas. TD has research funding from Merck Serono/Pfizer, honorarium/advisory board fees from Bayer, MSD, Sanofi Aventis, Amgen, Servier and Everything Genetic. PT received consultancy fees from SIRTEX medical. RS received research funding from Incyte, AAA, Astex, Bayer AG; consulting and advisory role: Eisai, Roche, Bayer Healthcare, SIRTEX; lecture fees: Bayer Healthcare, Falk Foundation.</p>
 </notes>
</notes>
